SCHEDULE: Blue Owl Capital Discloses 7.37% Stake in ImageneBio

Blue Owl Capital Holdings LP has reported a 7.37% beneficial ownership stake in ImageneBio, Inc., holding 823,785 shares of common stock.

Summary

• Blue Owl Capital Holdings LP has filed a Schedule 13G, disclosing beneficial ownership of 823,785 shares of ImageneBio, Inc. common stock.
• This represents a 7.37% stake in ImageneBio, Inc.'s outstanding common stock.
• The percentage is calculated based on 11,181,672 shares of common stock outstanding as of November 3, 2025, as reported in ImageneBio's Form S-1.
• Blue Owl Capital Holdings LP holds sole voting power and sole dispositive power over all 823,785 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of ImageneBio, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial stake by a reputable institutional investor like Blue Owl Capital Holdings LP can signal market confidence in ImageneBio, Inc. without implying any immediate control-related issues.

Positives

• A significant institutional investor, Blue Owl Capital Holdings LP, has taken a substantial 7.37% stake in ImageneBio, Inc., which can signal confidence in the company's long-term prospects.
• The acquisition of shares is stated to be in the ordinary course of business, suggesting a strategic investment rather than an activist position.

Negatives

• No specific negative information is contained within this beneficial ownership report.

Risks

• No specific risks are mentioned in this beneficial ownership report.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the disclosure of a significant stake by an institutional investor like Blue Owl Capital Holdings LP can often be interpreted positively by the market, suggesting a vote of confidence in ImageneBio, Inc.'s business model or future prospects. Such filings are standard regulatory disclosures and do not inherently indicate a shift in broader industry trends, but rather a specific investment decision.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership and does not contain performance metrics directly comparable to industry standards or specific projects.
• The significance lies in the identity of the investor and the size of the stake. A 7.37% stake is substantial enough to warrant attention from other institutional investors and market participants, similar to how major funds like BlackRock or Vanguard routinely disclose significant passive stakes in various companies across sectors.

Stakeholder Impact

• Shareholders: Existing shareholders may view the entry of a significant institutional investor positively, potentially leading to increased liquidity or perceived stability.
• Management: Management will be aware of a new large shareholder on their register, which could be seen as validation of their strategy.
• Potential Investors: The presence of Blue Owl Capital Holdings LP might attract other institutional investors to consider ImageneBio, Inc.

Key Dates

Recommendation

While the disclosure of a significant stake by Blue Owl Capital Holdings LP is a positive signal, this filing alone does not provide enough fundamental information about ImageneBio, Inc.'s operational performance, financial health, or strategic direction to warrant a 'buy' or 'sell' recommendation. It primarily indicates institutional interest. Investors should 'hold' and await further financial disclosures or operational updates from ImageneBio, Inc. to make a more informed decision, while acknowledging the potential positive sentiment from this institutional backing.

Keywords

ImageneBio Inc., Blue Owl Capital Holdings LP, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Equity Stake, SEC Filing